Skip to search formSkip to main contentSkip to account menu

nitecapone

Known as: 3-(3,4-dihydroxy-5-nitrobenzylidine)-2,4-pentanedione 
National Institutes of Health

Related topics

Related topics

7 relations

Broader (6)

Anti-Ulcer AgentAntioxidantsCatechol-O-methyltransferase inhibitorCatechols

Narrower (1)

OR 462

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Inhibitors of catechol‐O‐methyltransferase sensitize mice to pain
BACKGROUND AND PURPOSE Catechol‐O‐methyltransferase (COMT) inhibitors are used in Parkinson's disease in which pain is an… 
2000
2000
Direct analysis of nitrocatechol-type glucuronides in urine by capillary electrophoresis-electrospray ionisation mass spectrometry and tandem mass spectrometry.
Highly Cited
2000
Highly Cited
2000
Combined antioxidant and COMT inhibitor treatment reverses renal abnormalities in diabetic rats.
The development and progression of diabetic nephropathy is dependent on glucose homeostasis and many other contributing factors… 
1999
1999
Micellar electrokinetic capillary chromatography method for direct determination of glucuronides of entacapone and its (Z)-isomer in human urine.
1999
1999
Nitecapone reduces cardiac neutrophil accumulation in clinical open heart surgery.
BACKGROUND To study the effect of nitecapone, a novel antioxidant, on cardiac neutrophil activation during cardiopulmonary bypass… 
1997
1997
Glucuronidation of Entacapone, Nitecapone, Tolcapone, and Some Other Nitrocatechols by Rat Liver Microsomes
AbstractPurpose. Nitrocatechol COMT inhibitors are a new class of bioactive compounds, for which glucuronidation is the most… 
1995
1995
Antioxidant properties of nitecapone are potentiated by glutathione.
The effect of nitecapone (3[(3,4-dihydroxy-5-nitrophenyl) methylene]-2,4-pentanedione) on lipid peroxidation in guinea pig liver… 
1994
1994
Clinical Potential of Catechol-OMethyltransferase (COMT) Inhibitors as Adjuvants in Parkinson’s Disease
SummaryA series of new and selective catechol-O-methyltransferase (COMT) inhibitors have been developed. Entacapone, nitecapone… 
1993
1993
Nitecapone protects the Langendorff perfused heart against ischemia-reperfusion injury.
We assessed the protection afforded against myocardial ischemia/reperfusion by nitecapone in the Langendorff heart model using… 
1990
1990
Effect of nitecapone (OR-462) on the pharmacokinetics of levodopa and 3-O-methyldopa formation in cynomolgus monkeys.
3-O-Methyldopa (OMD) is the principal circulating metabolite formed from exogenously administered levodopa. We studied the effect… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)